Whereas patients with LC-IPF have few treatment options because of the risk of IPF progression following cancer treatment, a periostin-targeted therapeutic agent for LC-IPF may be clinically beneficial for both IPF and NSCLC in the future. The gene discussed is POSTN; the disease is idiopathic pulmonary fibrosis.